Back |
home / stock / pbyi / pbyi message board
Subject | By | Source | When |
---|---|---|---|
PBYi SOLID TUMORS APROVAL for FDA clay | CHARLIE125 | investorshub | 09/06/2019 1:49:43 PM |
$PBYI next aproval FDA for solid tumors | CHARLIE125 | investorshub | 09/06/2019 1:48:51 PM |
$PBYI | CHARLIE125 | investorshub | 08/22/2019 12:19:58 PM |
$PBYI i can say you pete that this $PBYI | CHARLIE125 | investorshub | 08/21/2019 1:28:41 PM |
$PBYI | CHARLIE125 | investorshub | 08/20/2019 1:41:49 PM |
PUMA is looking good and I see more | Brian903 | investorshub | 08/19/2019 8:48:14 PM |
PBYI next aproval next week solid tumors phase | CHARLIE125 | investorshub | 08/15/2019 1:58:03 PM |
JP MORGAN Is in contact with FDA and | CHARLIE125 | investorshub | 08/15/2019 1:55:37 PM |
22th july i said this.You can see it | CHARLIE125 | investorshub | 08/15/2019 1:54:23 PM |
* * $PBYI Video Chart 08-09-2019 * * | ClayTrader | investorshub | 08/09/2019 8:15:27 PM |
Everything You Need For Your Premarket Including PumaBiotechnology | behindthebid | investorshub | 08/09/2019 1:11:37 PM |
$PBYI 3 Months Chart http://www.stockscores.c | $Pistol Pete$ | investorshub | 07/23/2019 3:05:11 PM |
$PBYI current report impresive 7th august | CHARLIE125 | investorshub | 07/22/2019 6:39:33 PM |
Oops! Now what Charlie?? | girlfriend | investorshub | 07/08/2019 3:30:39 PM |
Puma | CHARLIE125 | investorshub | 06/18/2019 6:43:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib fo...
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...